Vanderbilt University researchers have received a five-year, $9 million grant from the National Institutes of Health (NIH) to design more effective flu vaccines and novel antibody therapies.

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

Researchers at Vanderbilt University, the University of Texas Medical Branch at Galveston and The Scripps Research Institute for the first time have shown how human antibodies can neutralize the Marburg virus, a close cousin to Ebola.

During the past five years, Vanderbilt University Medical Center has become a leader in “personalized medicine,” the use of genomic information to individualize patient care.

Vanderbilt University researchers have isolated Ebola-fighting human antibodies – the first of their kind – that could lead to a new treatment for the deadly virus.

Don’t panic over Ebola. But don’t ignore it, either. That was the take-home message for U.S. citizens from a “mini-hearing” held by U.S. Sen. Lamar Alexander, R-Tenn., at Vanderbilt University Medical Center on Wednesday with researchers and health officials from Vanderbilt and the State of Tennessee.